Our diagnostic solutions 


Unique biomarker test combining liquid and solid biopsies

Sample type:




Solid biopsy

Liquid biopsy

1 block or 25 slides

2 blood samples

Scroll down to discover

OncoSTRAT&GO screens the tumours much beyond the usual suspects

A unique combination of analyses to guide your treatment decision

This solution is an integrated approach that combines the analyses of a solid biopsy (by the next-generation sequencing of 313 genes, IHCs and additional tests) with the analysis of a blood biopsy. The blood profiling focuses either on the circulating tumor DNA (for deciphering tumor heterogeneity) or in DNA from blood cells (for studying specific germline gene alterations related to BRCAness phenotype that are challenging to detect in FFPE samples).

OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, hormonal therapies, chemotherapies and immunotherapies.

Sample Type:

Solid and liquid biopsy

Recommended for:

  • The following stage IV solid tumors in adults:
    • Non-small cell lung cancer
    • HR+, HER2+ and triple-negative breast cancer
    • Colorectal cancer
    • Cancer of unknown primary
    • Ovarian cancer
    • Pancreatic cancer
    • Prostate cancer

Gene panel:

  • 313 genes for the solid biopsy
  • Variable number of genes for the liquid biopsy depending on the cancer type 


  • 1 block or 25 slides (5 μm on SuperFrost Plus)
  • 1 blood sample (1x10 ml Streck tube or 1x10 ml EDTA tube)

Why to combine DNA, RNA and protein profiling?

A unique immunogram to properly predict response to immunotherapy

Our immunogram combines five different biomarkers for predicting clinical benefit of immune checkpoint inhibitors (ICIs): PD-L1 protein expression (FDA-approved marker), TMB, CD8+ T-cell infiltration, MSI (FDA-approved marker) and gene alterations leading to sensibility or resistance to ICIs. 

OncoSTRAT&GO patient case studies

Clinical evidences of OncoSTRAT&GO

Other diagnostic solutions

Cost-effective solution combining DNA, RNA and protein analysis of a tissue sample

OncoDEEP analyses solid biopsies by combining next-generation sequencing (313 genes), IHCs to study protein expression and additional tests. This complete tumor profiling allows to predict patient response to approved or experimental targeted drugs, hormonal therapies, immunotherapies and chemotherapies. The NGS panel is accurately designed according to oncologists’ needs in their current practice. Importantly, it includes an accurate determination of MSI, TMB and LOH. The NGS panel is regularly updated based on new findings reported in the literature in order to provide patients with the most cost-effective solution.

Smart and cost-effective liquid biopsy panels with selected key genes per tumor type

OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted and hormonal therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.

Personalised liquid biopsy for patient monitoring

OncoFOLLOW is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.

This assay is customised for each patient, as it analyses variants previously identified in the tumour of the patient.

In 2013, OncoDNA became the first company to launch a personalised liquid biopsy test.


Ordering a solution is very simple: Just log in to and select the solution(s) you are interested in. If you do not have a kit for sample collection, we will send you one.

After sample processing and interpretation by our expert team, a comprehensive report will be available for you on our platform OncoSHARE. In a simple and interactive manner, it will help you with the selection of the most appropriate treatments based on the unique signature of your patient's tumour. Moreover, you will be able to share the report with your colleagues.

For information regarding the price of our OncoSTRAT&GO biomarker test in your respective country, please contact our sales team.

Cannot find what you are looking for? Contact us! Our Scientific Support Teams are available to answer all your questions from Monday to Friday.

Related news